Jennifer Quizi, University of Ottawa

Research

Access To Care Car-T Leukemia Point-Of-Care Biomanufacturing

Latest papers

GPNMB-directed CAR T cell therapy against MiT/TFE-family fusion-driven solid tumors.
Nature cancer · 2026
CLIC-01: Manufacture and distribution of non-cryopreserved CAR-T cells for patients with CD19 positive hematologic malignancies.
Frontiers in immunology · 2022
Current challenges in the manufacture of clinical-grade autologous whole cell vaccines for hematological malignancies.
Cytotherapy · 2022

All 3 publications

Latest funding

Canadian-Made CD19 CAR-T Therapy for Refractory Systemic Sclerosis, from the Canadian Led Immunotherapies Collaborative (CLIC-03 Trial)
CIHR · 2025 · Co-investigator
$1,216,351
Development of Reovirus-based, orally administered, colon cancer vaccines.
CIHR · 2024 · Co-investigator
$818,550
Paving The Way to a Canadian Standard of Care with CAR-T Cellular Therapy: Phase II Trial of CD19 CAR-T for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia (CLIC-01A)
CIHR · 2022 · Principal investigator
$3,216,843

All 4 grants and awards

3 publications.

01

GPNMB-directed CAR T cell therapy against MiT/TFE-family fusion-driven solid tumors.

Zemp FJ, Breckenridge Z, Song H, Gill GS, Louie TL, Narta K, Liu H, Suh Y, Guignard L, Mandujano-Tinoco EA, Collao N, Pyczek J, Ellestad KK, Curry J, Langley J, John C, Mah LK, Rajwani J, Evseev D, Turk M, Benaoudia S, Alex J, Naumenko V, Manoharan VT, Mehrabadi MK, Smith HA, Gilbert GNY, Gillmor A, Verhey TB, Todesco HM, Osz K, Ahn BY, Bogossian A, Anderson C, Sikdar S, Rukunuddin S, Bismar TA, Heng DYC, Lawson K, Linehan WM, Pedersen H, Gordon PMK, McIntyre JB, MacGregor J, Garzia L, Brodeur-Robb K, DiFrancesco L, Ogilvie T, Schöffski P, Wozniak A, Holt RA, Bell J, Senger DL, Lewis V, Monument M, Khan O, Baudrier L, Billon P, Gabriel V, Biernaskie J, Potts K, Trpkov K, Hay K, Quizi J, Chan J, Saleh R, Henning JW, Prokopishyn NL, Shafey M, Morrissy AS, Mahoney DJ

Nature cancer2026

DOI: 10.1038/s43018-026-01194-3 PMID: 42387022

02

CLIC-01: Manufacture and distribution of non-cryopreserved CAR-T cells for patients with CD19 positive hematologic malignancies.

Kekre N, Hay KA, Webb JR, Mallick R, Balasundaram M, Sigrist MK, Clement AM, Nielsen JS, Quizi J, Yung E, Brown SD, Dreolini L, Waller DD, Smazynski J, Gierc NS, Loveless BC, Clark K, Dyer T, Hogg R, McCormick L, Gignac M, Bell S, Chapman DM, Bond D, Yong S, Fung R, Lockyer HM, Hodgson V, Murphy C, Subramanian A, Wiebe E, Yoganathan P, Medynski L, Vaillan DC, Black A, McDiarmid S, Kennah M, Hamelin L, Song K, Narayanan S, Rodrigo JA, Dupont S, Hawrysh T, Presseau J, Thavorn K, Lalu MM, Fergusson DA, Bell JC, Atkins H, Nelson BH, Holt RA

Frontiers in immunology2022

DOI: 10.3389/fimmu.2022.1074740 PMID: 36601119

03

Current challenges in the manufacture of clinical-grade autologous whole cell vaccines for hematological malignancies.

Bastin DJ, Quizi J, Kennedy MA, Kekre N, Auer RC

Cytotherapy2022

DOI: 10.1016/j.jcyt.2022.03.010 PMID: 35562303

Canadian-Made CD19 CAR-T Therapy for Refractory Systemic Sclerosis, from the Canadian Led Immunotherapies Collaborative (CLIC-03 Trial)

Co-investigatorCIHR2025Project Grant

Principal investigators: Kekre, Natasha; Hay, Kevin A; Holt, Rob; Hudson, Marie; Maltez, Nancy

Keywords: Car-T Cells; Immunotherapy; Scleroderma; Systemic Sclerosis

$1,216,351

Development of Reovirus-based, orally administered, colon cancer vaccines.

Co-investigatorCIHR2024Project Grant

Principal investigators: Alain, Tommy

Keywords: Colon Cancer; Mouse Models; Oncolytic Viruses; Orally Administered; Polyps And Pre-Malignant Lesions; Prevention; Recombinant Viruses; Reovirus; Reverse Genetics; Tumour Antigens

$818,550

Paving The Way to a Canadian Standard of Care with CAR-T Cellular Therapy: Phase II Trial of CD19 CAR-T for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia (CLIC-01A)

Principal investigatorCIHR2022Operating Grant: Clinical Trials Projects

Principal investigators: Kekre, Natasha; Bredeson, Christopher; Hawrysh, Terry A; Fergusson, Dean A; Hay, Kevin A; Holt, Rob; Quizi, Jennifer L; Thavorn, Kednapa

Keywords: Access To Care; Car-T; Leukemia; Point-Of-Care Biomanufacturing

$3,216,843

Paving The Way to a Canadian Standard of Care with CAR-T Cellular Therapy: Phase II Trial of CD19 CAR-T for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia (CLIC-01A)

Principal investigatorCIHR2022Operating Grant: Clinical Trials Projects - Indirect Costs

Principal investigators: Kekre, Natasha; Bredeson, Christopher; Hawrysh, Terry A; Fergusson, Dean A; Hay, Kevin A; Holt, Rob; Quizi, Jennifer L; Thavorn, Kednapa

Keywords: Access To Care; Car-T; Leukemia; Point-Of-Care Biomanufacturing

$804,211

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Frequent collaborators

Medicine
Department of Medicine
School of Epidemiology and Public Health
Pathology and Laboratory Medicine
Biochemistry, Microbiology and Immunology
Surgery
Biochemistry and Molecular Biology
Other

1 shared papers, latest 2026

Terry Hawrysh

Faculty

1 shared papers, latest 2022

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2022

Subject: Prospective PhD student: Access To Care Dear Professor Quizi, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "GPNMB-directed CAR T cell therapy against MiT/TFE-family fusion-driven solid tumors." (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Paving The Way to a Canadian Standard of Care with CAR-T Cellular Therapy: Phase II Trial of CD19 CAR-T for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia (CLIC-01A)" (2022), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]